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Abstract
In August 2002, 65 cases of Loa-associated neurological Serious Adverse Events were reported
after ivermectin treatment. The first signs, occurring within the 12–24 hours following treatment,
included fatigue, generalized arthralgia, and sometimes agitation, mutism, and incontinence.
Disorders of consciousness, including coma, generally appeared between 24 and 72 hours, and
showed a rapid variation with time. The most frequent objective neurological signs were
extrapyramidal. The patients presented with haemorrhages of the conjunctiva and of the retina.
Biological examinations showed a massive Loa microfilaruria, the passage of Loa microfilariae into
the cerebrospinal fluid, haematuria, and an increase in the C-reactive protein, all of which have been
correlated with the high intensity of the initial Loa microfilaraemia. Eosinophil counts decreased
dramatically within the first 24 hours, and then rose again rapidly. Electroencephalograms suggested
the existence of a diffuse pathological process within the first weeks; the abnormalities disappearing
after 3–6 months. Death may occur when patients are not properly managed, i.e. in the absence of
good nursing. However, some patients who recovered showed sequelae such as aphasia, episodic
amnesia, or extrapyramidal signs. The main risk factor for these encephalopathies is the intensity
of the initial Loa microfilaraemia. The disorders of consciousness may occur when there are
>50,000 Loa microfilariae per ml. The possible roles of co-factors, such as Loa strains, genetic
predisposition of individuals, co-infestations with other parasites, or alcohol consumption, seem to
be minor but they should be considered. The mechanisms of the post-ivermectin Loa-related
encephalopathies should be investigated to improve the management of patients developing the
condition.
Definitions
Serious Adverse Events (SAEs), are defined as "ones which
could be life-threatening, could result in permanent disa-
bility, or require hospitalization" (application text of the
Mectizan®  Donation Program, MDP). In the present
paper, we shall address only the issue of those SAEs which
occur after a standard dose of ivermectin (Mectizan®) for
the treatment of onchocerciasis (150 µg/kg), and which
are related to co-infection with Loa loa. Thus, we shall not
consider the ivermectin toxicosis related to overdose and
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passage of ivermectin through the blood-brain barrier [1],
nor the uncommon cases of serious reactions, such as
severe symptomatic postural hypotension or asthma
attacks, reported from areas where loiasis is not endemic
[2,3].
A first classification of SAEs was elaborated at a consulta-
tion organized by the MDP in Paris in October 1995.
Briefly, the cases to be considered have (a) to occur in
individuals who were previously healthy, (b) to be tempo-
rally related to treatment with Mectizan®, i.e. with central
nervous system (CNS) signs and symptoms appearing
within five days of treatment, and (c) to progress to coma
without remission. In addition, the coma is usually asso-
ciated with fever, and not with seizures. That being said,
the cases were classified as (a) definite cases of Loa
encephalopathy, (b) probable cases of Loa encephalopa-
thy, and (c) coma events in a Loa loa endemic area. The
definite cases were defined by the observation, in brain
tissue, of microscopic findings consistent with Loa
encephalopathy, i.e. a vasculopathy with evidence of L. loa
microfilariae (mf) as a likely aetiology. The probable cases
were defined by the presence of a Loa  microfilaraemia
above a given value (> 10,000 mf/ml if measured before
treatment, or > 1,000 mf/ml if the sample is obtained after
treatment) and/or the presence of L. loa mf in the cerebro-
spinal fluid (CSF). The last category includes cases of
coma occurring in patients living in areas endemic for loi-
asis, who have been treated with ivermectin but for whom
no laboratory results are available to support the diagno-
sis of Loa encephalopathy. An additional category of "pos-
sible cases of Loa encephalopathy" was added recently to
include those patients for whom the Loa microfilaraemia
was not assessed quantitatively, but who showed Loa mf
in their blood smear.
Besides this classification, which is very useful, observa-
tions made during a study performed in the Lekie area of
the Republic of Cameroon to evaluate the incidence rate
of, and the risk factors for, post-ivermectin encephalopa-
thies have led us to elaborate another complementary
classification, aimed at describing the seriousness of the
condition on the basis of the severity and duration of the
functional impairment [4,5]. Four degrees have been
defined.
1) Mild reactions; 2) Marked reactions; 3) Serious non-
neurological reactions; 4) Serious neurological reactions.
1) Mild reactions are the ones that are not accompanied
by any functional impairment.
2) Marked reactions are similar in nature to the mild reac-
tions (headache, joint pains, itching, oedema) but their
intensity is such that they are accompanied by functional
impairment requiring, for several days, assistance in per-
forming some everyday natural functions and household
activities.
3) Serious non-neurological reactions correspond to con-
ditions associated with functional impairment that
require, for at last one week, full-time assistance; patients
usually stay in bed or in armchairs and have difficulty in
standing up or walking, but do not show disorders of con-
sciousness or objective neurological signs.
4) Serious neurological reactions are associated with dis-
orders of consciousness and neurological signs.
This classification has the advantage of being relatively
simple to apply in the field, and of taking into account
both the degree of impairment, and its duration. How-
ever, although we are aware that this may overwork the
medical personnel (even the Glasgow coma score is diffi-
cult to obtain in medical records of the cases) when the
patients are hospitalized, it could be useful to use more
accurate scales, such as the Karnofsky performance scale
or, may be better still, the palliative performance scale [6].
It is clear that the only life-threatening events are the seri-
ous neurological reactions. However, the other serious
and marked reactions, which are much more frequent,
have an important impact on the populations' perception
of ivermectin, and play a major role in lowering their
acceptance of the drug, as is often reported from those
areas where loiasis is co-endemic with onchocerciasis.
Description of sources regarding clinical and 
biological features
From the inception of the Mectizan® Donation Program in
1988 to January 2002, the total number of SAEs reported
to the MDP was 187, including 159 from Cameroon, 14
from Sudan, 6 from Nigeria, 5 from the Democratic
Republic of the Congo (DRC), and one from the Central
African Republic (CAR). In August 2002, the number rose
to 207 (176 from Cameroon), out of which 65 were clas-
sified as probable or possible cases of Loa encephalopathy
temporally related to treatment with Mectizan®. The
present paper will summarize observations made on only
35 cases, all from Cameroon, for which we have some
information. They include the five cases described in
detail by Boussinesq et al., [5], eight cases hospitalized in
May 1999 at the Central Hospital of Yaoundé (CHY), 16
patients who also developed SAEs in May 1999, but for
whom we have only the standardized form for reporting
of SAEs, and 6 cases from the District of Malantouen
(West Province).
Regarding the biological aspects, along with the data pre-
sented by Boussinesq et al., [5], we have re-analysed someFilaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S4
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results of the study reported by Ducorps et al., [7]. This
study, which aimed at evaluating the clinical and biologi-
cal changes after ivermectin treatment in patients with a
significant  Loa  microfilaraemia, was performed at the
CHY. A total of 112 patients, each with more than 3,000
Loa  mf per ml of blood, agreed to participate. These
patients were resident in the Lekie area (Central Province,
Cameroon). Twenty-six of them were co-infected by Man-
sonella perstans, (median load of 250 M. perstans mf/ml).
No skin snips were taken before inclusion in the study,
but these patients had been examined for onchocerciasis
several months previously (maximum: one year). At that
time, 52 of the 112 patients were co-infected with both
Loa loa and  Onchocerca volvulus, but the microfilarial
counts of the latter parasite were very low: only 13
patients had 10 mf per skin snip or more, and the median
O. volvulus microfilarial load in the infected individuals
was 3 mf per skin snip.
Clinical picture
Clinical signs and symptoms within the 3 days following 
treatment
The vast majority of patients developing an SAE com-
plained of various symptoms developing within the 12–
24 hours following treatment (Day 1, D1). The main com-
plaints were fatigue, which could be severe and accompa-
nied by anorexia, headache, and generalized arthralgia.
Among the latter, the patients often complained of severe
lumbar pain, which could be objectively appreciated by
the characteristic bent-forward walk of the patients. The
subjects often said that they were "broken". Stomach pain
and diarrhoea have also been reported at D1.
Besides these signs, which are classically reported after
ivermectin treatment of patients not infected with Loa loa,
but at a lower degree of seriousness, more alarming signs
sometimes developed as soon as D1. These were confu-
sion, agitation, dysarthria, mutism, and incontinence.
However, more often these signs were reported later, at
Day 2 (D2) or Day 3 (D3). In their study, Ducorps et al.,
[7] measured the Karnofsky performance scale every day
during the week after treatment. Among those patients
with a pre-treatment Loa  microfilaraemia exceeding
30,000 mf/ml, the proportions of patients presenting a
functional impairment at D1, D2, D3 and Day 4 (D4),
were 4%, 36%, 32%, and 37%, respectively. Thus, it
appears that the neurological involvement generally
appears first at D2. Although some cases of coma have
been reported as soon as D2, this condition usually devel-
ops at D3 or D4.
It seems that the various signs related to oral expression
(dysarthria, mutism, and confusion) are typical of the
condition, as well as incontinence, which usually occurs
in the course of development of the symptoms. This
incontinence is often only urinary, but faecal inconti-
nence may appear when the condition worsens.
All these signs are usually accompanied by fever, which
tends to reach its highest level at D1, but is often reported
only at D2–D3. The temperature may rise up to 40°C.
The neurological condition
Detailed information on the objective neurological signs
shown by the patients has been presented by Boussinesq
et al., [5]. Very few additional data are available from the
medical records and forms from the other cases, even
those hospitalized at CHY in 1999. When the cases are
appropriately managed, it seems that the worst Glasgow
scores are recorded on D4–D5. However, when the
patients develop complications (see below), the neuro-
logical condition may continue to worsen progressively. A
striking feature observed in some patients is the rapid var-
iation with time of the degree of disorders of conscious-
ness. Generally, the patients do not have seizures. The
only cases reported so far are Bi. G., a little girl aged 6
years, who had seizures at D13 and D19, without fever;
and Ob. JJ, a male 20-years old, whose condition at D2
included generalized itching, followed by disorders of
consciousness and later by seizures and vomiting. On sys-
tematic examination, motor or sensory deficits were not
found, but tendon reflexes were most often abolished or
diminished, though they were brisk in some cases. Usu-
ally, there was no Babinski's sign, but meningeal signs
were found in some patients. The signs most constantly
found were extrapyramidal. Hypertonia was frequent, and
the cogwheel phenomenon was one of the last signs to
disappear.
To summarize, the condition is very variable between
cases and, for a given case, may change very rapidly from
one examination to another. This variability over time
seems to be characteristic of the condition.
Associated clinical signs and symptoms
Ophthalmology
One of the signs associated with the post-ivermectin Loa-
related SAEs is the appearance of haemorrhages in the
palpebral conjunctiva (HPC) and of retinal lesions (RL),
described by Fobi et al., [8]. The HPCs were rarely seen at
D1, but were always present between D2 and D5. After
D6, they tended to diminish, and they disappear without
sequelae around 10 days after treatment. These HPCs have
a typical appearance: the main trunk of the vessels appear
to be normal, but a blot haemorrhage is present at the tip
of the vessel (see photographs in [8]). Sometimes, several
haemorrhages coalesce to form a single large haemor-
rhage. These lesions are located below the lid margin,
whereas no lesions have been seen in the bulbar conjunc-
tiva. A conjunctival biopsy collected at D5 from oneFilaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S4
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patient with a pre-treatment load of 86,400 Loa mf/ml
showed marked vascular congestion, with erythrodiaped-
esis and interstitial haemorrhages; the vascular lumina
were widely open and filled with red blood cells, but no
mf were seen. This appearance suggested that the HPCs
were due to a passive congestion caused by obstruction of
the small vessels located downstream. The risk of develop-
ing HPCs after ivermectin treatment was found to be sig-
nificantly increased when the Loa  microfilaraemia
exceeded 1,000 mf per ml (reference patients: those with
0 mf/ml). Thus, some patients may present HPCs without
developing SAEs. However, due to their early appearance
(D2), these lesions can be considered as a warning signal
indicating patients who might be about to develop neuro-
logical reactions. In addition, it has been proposed to
examine systematically for HPCs all patients exhibiting
SAEs [8]: the presence of such lesions constitutes an argu-
ment in favour of the implication of Loa in the condition.
Lastly, it might be useful to investigate the possibility that
HPCs may occur spontaneously; such a phenomenon
would probably be even less frequent than after treat-
ment, but one may consider the possibility that this sign
may help to identify patients with considerable Loa micro-
filaraemias.
Another feature reported from patients with post-ivermec-
tin Loa-related SAEs is the existence of retinal haemor-
rhages and "cotton wool exudates" corresponding to areas
of nerve fibre layer ischaemia. These are mainly located at
the end of blood vessels, particularly temporal to the mac-
ula. The haemorrhages are usually intraretinal but can
also be pre-retinal. They are mostly located at the tip of
blood vessels, and often have one or two white spots in
their centre, giving them an appearance close to that of
Roth's spots (see photographs in [8]). In some cases tiny
venules and arterioles appear completely empty, and have
the aspect of white filaments. The interval between iver-
mectin treatment and appearance of these lesions is not
accurately known, however, it seems that they are usually
seen after D3, and that they may still be visible up to 3–4
weeks later. Such retinal lesions have also been seen in
post-diethylcarbamazine Loa-related SAEs, and it appears
that rare cases have also been reported in untreated
patients infected with Loa loa (see review in [8]). As for the
HPCs, we think that retinal lesions should be looked for
when a patient develops a neurological condition possi-
bly related to Loa infection, and that the presence of such
typical lesions is a strong argument in favour of the impli-
cation of Loa in the condition.
Nephrology
Loiasis may be associated with proteinuria and/or haema-
turia, and it may provoke membranoproliferative and
membranous glomerulonephritis [9–15]. However, sev-
eral observations also show that ivermectin may provoke
renal complications; and it has been shown (see below),
that the drug induces the passage of Loa mf into the urine,
and also haematuria. Sometimes, this can be associated
with serious signs and symptoms. For instance, one
patient described by Cruel et al., [16] developed an acute
nephropathy several hours after ivermectin treatment
although he was harbouring only a fairly low Loa micro-
filaraemia (400 mf/ml). Examination of a renal biopsy in
this patient showed numerous mf in the glomeruli, and
the presence of immune complexes. The only patient who
developed a coma in the study by Ducorps et al., [7] also
presented with glomerulonephritis, with a proteinuria at
D3, and anuria at D4–D5. It is interesting to note that
renal changes have been also reported after ivermectin
treatment of humans with onchocerciasis [17], and after
ivermectin treatment of Dirofilaria immitis-infected dogs
[18].
Complications
It seems that the main complications of post-ivermectin
Loa-related SAEs are related to a prolonged hospitaliza-
tion, or to a long stay in bed. After 10–20 days, the coma-
tose patients readily develop bedsores, and this is a signal
of poor prognosis. Furthermore, the patients are at risk of
dehydration, of deterioration of an underlying condition
(e.g. diabetes), and of developing nosocomial (especially
broncho-pulmonary) infections. Intense nursing is thus
the main element of the management of the patients. But
besides these non-specific complications, several cases of
neurological sequelae, which are probably related to the
pathological processes associated with the Loa encepha-
lopathy, have also been reported (see under "Outcome"
below).
Biological, and other complementary 
examinations
Parasitological examinations
Loa microfilaraemia decreases very sharply after ivermec-
tin treatment: in the patients who participated in the study
by Ducorps et al., [7], and who had been treated with a
single dose of 200 µg/kg, the loads recorded 24, 48 and 72
hours after treatment were about 40%, 25%, and 20%,
respectively, of their initial values. The reduction rate is
similar whatever the pre-treatment microfilaraemia. After
D3, the loads continue to decrease, but in a very slow
manner [19].
Ivermectin also provokes a massive Loa  microfilaruria,
whose incidence is correlated with microfilarial load. Dur-
ing the study reported by Ducorps et al., [7], a Loa micro-
filaruria was rarely found before treatment, being
observed in only 4% of those patients with a microfilarae-
mia above 30,000 mf/ml. At D1, Loa mf were found in the
urine of 24% and 57% of those patients with initial loads
of 15,000 – 30,000 and > 30,000 mf/ml, respectively. TheFilaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S4
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values recorded in these two groups were still higher at D3
(54 and 79%, respectively), and then decreased at D4. The
microfilarial counts in the urine followed the same pat-
tern over time, as did the prevalence, with a sharp decrease
after D4. In all cases, these mf were mobile, and thus alive.
The most characteristic feature of the post-ivermectin Loa-
related SAEs is the passage of Loa mf into the CSF. In the
study reported by Ducorps et al., [7] Loa mf were found at
D1 in the CSF of 17%, 25%, and 13% of the patients har-
bouring pre-treatment microfilaraemias < 15,000, 15,000
– 30,000, and > 30,000 mf/ml, respectively. The corre-
sponding figures at D3 were 25%, 60%, and 77%. To ver-
ify whether these mf were or were not in the CSF before
treatment, lumbar punctures were done before treatment
in 10 patients with Loa loads above 10,000 mf/ml, none
of them had mf in the CSF before treatment, but four
showed a microfilarorachia at D3. As in the urine, these
mf were alive. It is difficult to assess at what interval after
treatment the Loa mf disappear from the CSF. They have
been found two weeks after, but the examinations done in
the patient of Ducorps et al., [7], who showed counts of
102 and 14 mf/ml of CSF at D6 and D13, respectively,
suggest that the densities of Loa mf in the CSF decrease
rapidly after one week.
These observations suggest that ivermectin treatment
induces the Loa  mf to flee from the blood circulation.
Such a phenomenon had been reported in patients
infected with O. volvulus, and treated with diethylcar-
bamazine (DEC) [20,21].
Proteinuria and haematuria
Before treatment, less than 10% of the patients included
in the study by Ducorps et al., [7] showed evidence of
microscopic haematuria, whatever their microfilaraemia.
This proportion increased progressively after treatment
and, by D3–D4, 18% of patients with <15,000 mf/ml,
19% of those with 15,000–30,000 mf/ml, and 35% of the
individuals harbouring >30,000 mf/ml developed haema-
turia. Ivermectin treatment also provoked the appearance
of proteinuria, with an incidence of 70% in those patients
with > 30,000 mf/ml [7].
Biochemical and cytological results in the CSF
Besides the mf (see above), and a moderate increase in the
levels of proteins, which is observed in some cases only,
no abnormalities have been recorded in the CSF.
Leukocytes, and in particular, eosinophils
The data collected as part of the study published by
Ducorps  et al., [7] show an increase in the leukocyte
counts between D0 (pre-treatment) and D3. The counts
varied from 7,120 to 7,280 per mm3 in the group with less
than 15,000 mf/ml, from 7,510 to 8,080 per mm3 in the
patients with 15,000–30,000 mf/ml, and from 6,960 to
8,100 per mm3 in the individuals harbouring more than
30,000 mf/ml. The same study shows that the eosinophil
counts decrease dramatically within the first 24 hours
after treatment, and that this decrease becomes more
marked as the initial microfilaraemia increases. The
counts recorded at D1 in the patients harbouring <
15,000, 15,000 – 30,000 and > 30,000 mf/ml were 84%,
62%, and 50%, respectively, of the pre-treatment counts
recorded in these 3 groups. At an individual level, there
was a positive correlation between the drop in the micro-
filaraemia from D0 to D1, and the decrease in the eosi-
nophil counts during the same interval. After this
dramatic decrease, the eosinophilia rose again rapidly,
and at D3, the values recorded were 120–130% of the ini-
tial counts in all the three groups of patients. The changes
after D3 were not studied by Ducorps et al., [7], but Mar-
tin-Prével et al., [22] reported a marked increase in the
numbers of eosinophils 8–10 days after treatment with
ivermectin, and then a slow decrease in the counts, with
values similar to, and less than half of, the pre-treatment
ones, at D23–D33, and D92–D109, respectively.
As indicated above, 52 of the 112 patients included in this
study were also co-infected with O. volvulus, but with very
low microfilarial loads. We have compared, within each
group of patients, defined according to their Loa micro-
filaraemia (< 15,000; 15,000 – 30,000; and > 30,000 Loa
mf/ml), the mean decrease in the eosinophil counts in the
O. volvulus snip positive and the O. volvulus snip negative
patients. In the two groups with the highest Loa loads, the
values were similar, but with a slightly greater decrease in
the patients with no skin O. volvulus mf (in the patients
with 15,000 – 30,000 Loa mf/ml: decrease of 633 vs. 698
eosinophils per mm3; and in the patients with > 30,000
Loa mf/ml: decrease of 602 vs. 722 eosinophils per mm3).
In both groups, the mean Loa microfilarial loads were
similar for snip positive and snip negative patients. Thus,
it seems that, in this study, infection with O. volvulus
played a minor role in the decrease in eosinophilia
between D0 and D1, and that the phenomenon can be
attributed to the infection with Loa.
Besides these global trends, one should note that in some
patients who develop Loa-related post-ivermectin SAEs, a
dramatic drop in the eosinophilia can be observed a
number of days after treatment. This was the case in two
patients reported by Boussinesq et al., [5]: the patient
described as "case 1" had a nil eosinophilia at D13; and in
"case 3" the eosinophil counts at D4 and D7 were 1,700
and 0 per mm3, respectively. This same phenomenon was
also observed in two of the patients who were hospital-
ized at the CHY, in 1999, and who had a full blood count.
One of them (Ol. Aw. L.) had 41 eosinophils per mm3 at
D6, and the other (On. Ay. S.) had a nil count at D11.Filaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S4
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The global changes in eosinophil counts recorded after
ivermectin treatment in patients infected with L. loa are
similar to those recorded by Ackerman et al., [23] and
Cooper et al., [24] in onchocerciasis patients after treat-
ment with DEC or ivermectin. These authors arrived at the
conclusion that the "Mazzotti reaction", and its severity,
were associated with eosinophil sequestration and activa-
tion-degranulation. This feature confirmed previous
observations on the preponderant role of eosinophils in
the development of the Mazzotti reaction [25–27]. Simi-
lar processes probably play a major role in the initiation
of the post-ivermectin Loa-related reactions, however, this
may not account for all the signs making up the picture of
post-filaricide Loa-related SAEs.
Other elements related to inflammation
No data are available concerning the changes in the eryth-
rocyte sedimentation rate after ivermectin treatment of
patients with Loa loa. In the study by Ducorps et al., [7], a
marked increase in the C reactive protein (CRP) was
observed within the 3 days following ivermectin treat-
ment. The concentrations increased from 5.0 to 12.0 mg/
l in the group with initial loads < 15,000 mf/ml, from 1.0
to 24.1 mg/l in the group with 15,000–30,000 mf/ml, and
from 5.0 to 53.3 mg/l in the group harbouring > 30,000
mf/ml. It has also been shown in another study group that
the CRP levels decrease between D3 and D7 [19]. In the
study by Ducorps et al., [7], a slight but significant
increase in the complement component 3 (C3) has been
recorded between D0 and D3: the values changed from
0.71 to 0.74 mg/ml in the group with the lowest Loa
counts, and from 0.65 to 0.69 mg/ml in the two other
groups.
Other biological examinations
Ducorps et al., [7] reported a moderate but significant
decrease (by about 15%) in the alkaline phosphatase
between D0 and D3, whereas the mean values of aspartate
and alanine aminotransferases (ASAT and ALAT)
remained stable. A moderate increase (by 10%) in the cre-
atine phosphokinase (CPK) was also reported by these
authors.
Electroencephalography
Repeated electroencephalograms (EEG) were done in two
patients who participated in the trial by Gardon et al., [4].
As indicated by Boussinesq et al., [5], one patient showed,
"at D15, periodic occurrence, during hyperventilation, of
diffuse discharges of large amplitude; on D146, the trac-
ing was asymmetric and characterized by slow activity
with additional spikes, indicating focal activities in the
right parieto-occipital area, which worsened during hyper-
ventilation; on D233 the abnormalities had disappeared
and the tracing did not show any pathologic activity". The
EEG done on D19 on the other patient showed "a slow
tracing with spontaneous occurrence of diffuse, paroxys-
mal, and monomorphic theta activity that lasted 2–3 sec.;
the slowing of activity was increased by hyperventilation;
by D105 an improvement was recorded but focal abnor-
malities persisted in the left occipital region, especially
during hyperventilation; by D159 all previously recorded
abnormalities had disappeared".
These results suggest the existence of a diffuse pathologi-
cal process in the brain within the first weeks; that lesions
are still present 3–6 months after the SAE; and that EEG
abnormalities disappear only after this interval. It should
be noticed that in the first of the two cases reported, the
patient, in spite of his normal EEG after 7 months, may be
considered as having mild sequelae. Although this may be
regarded as a subjective observation, his relatives said that
his mood had changed and that he was significantly
calmer than before treatment.
Computerized axial tomography
Tomography was performed in two of the cases of Loa-
related post-ivermectin SAEs hospitalized at the CHY in
April 1999. In one case, the examination was done at D14,
and showed a cortico-sub-cortical atrophy (probably
related to pre-existing vascular phenomena), and
hypodense areas of the brain stem (lateralised at the right
side), and in the inner temporal areas (at both sides);
there was no sign of cerebral oedema. In the other case,




When appropriately managed, most of the patients devel-
oping  Loa-related post-ivermectin SAEs recovered com-
pletely, without sequelae. The neurological examination
became normal after several weeks, usually before one
month, the last signs to disappear being the extrapyrami-
dal signs (cogwheel phenomenon). As indicated above,
the EEG still showed abnormalities after several months,
but became normal within 6–7 months.
Death
If the patients remain confined to bed for a long time they
may develop complications, the most frequent one being
bedsores. As the latter are most often, in the African con-
text, not appropriately managed, superinfections appear
and the patient may die after several weeks from septic
complications, dehydration, and malnutrition. Fairly
detailed information is available for several patients who
died from Loa-related post-ivermectin SAEs, and may be
summarized as follows (all patients developed bedsores,
which are not noted below): (i) case described in [28]:
death at D25, due to gastrointestinal bleeding possibly
due to corticosteroid treatment; (ii) case 1 of [5]: death atFilaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S4
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D21, partly due to a large abscess on one cheek; (iii) Ol.
Aw. L. (dead at CHY in 1999): death at D18 due to a septic
shock probably favoured by a pre-existing diabetes; (iv)
On. Ay. S. (dead at CHY in 1999): death at D48, from pro-
gressive decline; (v) Nt. D. (dead at CHY in 1999): death
at D6, high fever, cause unknown; (vi) Tc. J. (dead at
Malantouen hospital in 1999): death at D6, high fever,
cause unknown.
Recovery with sequelae
In other cases, the patients recover progressively, but with
more or less severe sequelae. The latter can be summa-
rized as follows: (i) case 2 of [5], change in mood, accord-
ing to the relatives, calmer than before treatment; (ii) case
3 of [5], episodic amnesia, leading to interruption of
school attendance; (iii) Bi. G. (hospitalized at CHY in
1999), dysphasia; (iv) On. A. (hospitalized at CHY in
1999), "scatterbrained and less gallant" than before treat-
ment, according to the family, cogwheel phenomenon;
(v) No. JM (hospitalized at Okola Hospital in 1999),
walking disorders, cogwheel phenomenon.
These sequelae are a cause of concern, but in all cases they
are much less severe than those recorded in patients who
developed SAEs after DEC treatment.
Epidemiology
Main risk factor: Loa loa microfilaraemia
Demonstration
The fact that the Loa microfilaraemia is by far the main
risk factor for post-ivermectin SAEs has been demon-
strated by Gardon et al., [4]. This result is consistent with
all the previous observations on the occurrence of SAEs
after other filaricide treatment, especially DEC. It is prob-
ably true that co-factors also exist, because not all subjects
with high Loa microfilaraemia develop an SAE after iver-
mectin, but we feel that they play a minor role, and that
further research to prevent or manage the post-ivermectin
SAEs should focus on the pathological processes involving
Loa loa itself.
Thresholds of risk
The criteria for defining probable cases of Loa-related
encephalopathy include threshold values for Loa micro-
filarial loads (>10,000 mf/ml if measured before ivermec-
tin treatment, or >1,000 mf/ml if the sample is obtained
after treatment). As these values were determined in 1996,
and although determining such "threshold" values may
be regarded as artificial because of the progressive aspect
of the phenomenon, one may wonder whether they are
still valid in 2002.
Concerning those SAEs with disorders of consciousness,
information on the pre-treatment Loa microfilaraemia is
available for only 5 cases [5,29]. In all of these, the counts
were >50,000 Loa mf per ml. It is interesting to notice that
this value is exactly the same as the one presented by Fain
[30] as being the threshold above which there is a risk of
post-DEC Loa encephalopathy.
Besides the cases with objective neurological signs, Gar-
don  et al., [4] have defined serious non-neurological
cases, i.e. with no objective signs but a functional impair-
ment requiring full-time assistance for at least one week.
The incidence of such reactions is closely related to the Loa
microfilaraemia and may be estimated using the follow-
ing formula [4,31]:
Probit (incidence) = 3.96 + (1.87 [loge(x) - 11.06]),
where x is the Loa microfilaraemia per ml.
When one replaces x by various values, one obtains the
following results for the probability of developing a seri-
ous reaction (whether or not neurological) after ivermec-
tin treatment: 0.7% when x  = 30,000; 2.7% when x  =
40,000; 7.0% when x = 50,000; 27.0% when x = 80,000;
42.0% when x = 100,000; 71.0% when x = 150,000; and
97.0% when x = 300,000 mf/ml.
From these results, one may consider that the value of
10,000 Loa mf/ml, which has been proposed as a criterion
for defining "probable case of Loa-related encephalopa-
thy" is fairly low. However, we would be inclined to keep
this value for the time being, because the quantitative
assessment of mf concentrations in blood smears by
microscopy is often not very accurate.
Besides this, one should consider the values of microfila-
raemia recorded after treatment, which are of course the
only ones which are usually available. As indicated above,
the Loa microfilarial loads recorded 24, 48 and 72 hours
after treatment in patients who received ivermectin at a
dose of 200 µg/kg were about 40%, 25%, and 20%,
respectively, of the initial values. In the trial reported by
Kamgno et al., [19], the number of patients, as well as
their Loa loads, were lower than those reported in the
study by Ducorps et al., [7], but the patients were treated
with the standard dose of ivermectin recommended for
treatment of onchocerciasis, and the follow-up was done
every day from D0 to D7, and then on D15 and D30.
From all these data, one may consider that after a single
dose of 150 µg/kg, the Loa loads at D1–D3, D4–D7, and
D7–D15 are about 25–40%, 20–25%, and 15–20%,
respectively, of the initial values. This would mean that
the threshold values for defining a probable case of Loa-
related post-ivermectin SAEs would be 2,500–4,000,
2,000–2,500, and 1,500–2,000 mf/ml, respectively, if the
blood smear has been done at D1–D3, D4–D7, or D7–
D15 after a standard dose of ivermectin. However, oneFilaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S4
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should keep in mind that the response to treatment may
vary widely between individuals, and that should the
severity of the reactions be also related to the rapidity of
the decrease in the microfilarial loads, lower values than
those quoted above might be recorded in some patients
after treatment. The values obtained at longer term (3, 6
or 12 months after a first single dose) have been presented
by several authors [32–34]. The results show that, in those
patients with more than 30,000 mf/ml, the individual risk
of developing a SAE related to Loa infection would be
reduced by over 90% if a second Mectizan® treatment were
given 6–12 months after the first [34].
Other possible risk factors
Even though it is clear that high Loa microfilaraemia is the
main factor associated with the risk of developing a post-
ivermectin  Loa-related SAE, one may wonder whether
other factors may act as co-factors. Our studies show that
not all the patients whose Loa loads exceed the threshold
of risk develop an SAE. One may also wonder whether
some, as yet unrevealed, specific factor exists in Cam-
eroon, where most of the cases of SAEs have been
reported.
Loa loa parasitic strains
Even if neurological SAEs have been reported from many
countries such as Gabon [35], CAR [36], Democratic
Republic of the Congo and Sudan, most (about 85%) of
the post-ivermectin SAEs have been reported from Cam-
eroon. This is probably mainly related to the fact that the
Loa microfilarial loads are higher in the latter country,
and/or to differences in the surveillance procedure during
the distributions, but it might also suggest that the local
parasitic "strain" in Cameroon is more pathogenic than
the others. In this respect, parasite samples collected in
Cameroon, Gabon, Nigeria, Congo were sent to Dr. T.
Unnasch, who analysed the genetic polymorphism in
potentially interesting loci from the Loa loa genome. These
studies are still ongoing. However, it is clear that even if a
specific parasite population exists in Cameroon, this does
not necessarily mean that this specificity is associated with
the risk of being involved in development of SAEs. In
addition, one should keep in mind that the epidemiology
of the post-ivermectin Loa-related SAEs is probably similar
to that of the post-DEC encephalopathies, and that,
regarding the latter, it is clear that there was no geographic
clustering of the cases. Assuming this, one should con-
sider that one of the main areas at risk, presently, is
located in the DRC, where so many cases of post-DEC
SAEs were seen (80–90 cases within 10 years in a single
hospital in the Mayumbe area [30]) that the physician
who managed them did not feel that it was useful to pub-
lish any description.
Genetic predisposition of some populations
Again, the high number of cases reported from Cameroon
may suggest that the local human population has specific
risk cofactors, possibly genetic ones. The arguments pre-
sented in the preceding paragraph also apply when con-
sidering this possibility.
Predisposition of some individuals
At an individual level, it has been demonstrated that sex is
not a factor associated with an increased risk of develop-
ing a serious reaction to ivermectin. However, susceptibil-
ity does appear to be age-related [4]. For a given Loa load,
people aged 30–44 develop SAEs significantly more often
(P = 0.032) than those in the reference class (age 15–29).
Conversely, the risk is not increased for persons aged 45–
59, and those aged 60 and above. This result is difficult to
explain, but it is possible that specific co-factors exist more
often in individuals aged 30–40. Logistic regression anal-
yses have also been done on the factors associated with
the occurrence of haemorrhages of the palpebral conjunc-
tiva, a feature which is part of the global picture of the
SAEs. In this analysis, it was found that the risk of devel-
oping an HPC was significantly higher (P < 0.001) in
males; conversely, age was not found to be associated with
the occurrence of HPCs [8].
Co-infestations
Co-infestation with O. volvulus does not seem to have to
be regarded as a cofactor associated with the SAEs. Many
cases of SAE were reported from patients living in areas
where onchocerciasis is hypoendemic or non endemic.
This was observed in patients who came from the District
of Okola (located some 20 km north-west of Yaoundé, in
the Lekie Division), and who were reported in April 1999,
and in two patients who developed disorders of con-
sciousness in Ngat (village located some 50 km south of
Yaoundé, in the Nyong and So'o Division), where loiasis
is highly endemic, and where there is no transmission of
onchocerciasis [29]. Two of the patients who developed
an SAE had undergone both a blood smear and a skin
biopsy before treatment. The first one is the one described
in [28]; the skin snip was positive, but the microfilarial
load is unknown. The second case is the one described by
Ducorps et al., [7]; no mf of O. volvulus was found in the
skin of this patient.
In the analysis performed by Gardon et al., [4], M. perstans
microfilaraemia was not found to be significantly associ-
ated with the development of serious reactions, but the P-
value (0.054) was near the limit of significance. In the
study on the factors associated with the occurrence of
HPCs, it was found that, besides the Loa  microfilarial
load, which was the main factor, and male sex, M. perstans
microfilaraemia was also a variable associated with the
risk of developing HPCs, with a P-value of 0.012 [8]. ThisFilaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S4
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is probably explained by the existence in the human pop-
ulation of a positive association between Loa and M. per-
stans infections [37,38].
Njoo  et al., [39] performed a study on onchocerciasis
patients treated with ivermectin, and did not find any rela-
tionship between the occurrence and extent of side effects
and the severity of concurrent intestinal parasitic infec-
tions (Ascaris lumbricoides, Trichuris trichiura, hookworm,
Schistosoma mansoni).
The classification of the cases produced in October 1995
specified that, besides the required criteria, a helpful piece
of information to define probable cases of Loa-encepha-
lopathy would be the absence of Plasmodium in the blood
smear. This is indeed an important issue to address
because the clinical pictures of Loa-related SAEs and cere-
bral malaria present many similarities, including fever,
disorders of consciousness, and even retinal haemor-
rhages with white centres [40].
Examination for Plasmodium falciparum has been done in
only some of the cases of post-ivermectin SAEs. In most
cases, no malaria parasite was found, but in some cases
high numbers of Loa microfilariae were associated with
Plasmodium. Whether the presence of Plasmodium  can
facilitate the development of Loa encephalopathy is not
known.
The areas of Cameroon where the cases of post-ivermectin
SAEs come from are not endemic for trypanosomiasis.
The clinical condition of the patients before treatment did
not suggest that they could be infected with Trypanosoma.
However, patients who presented both Loa  mf and
Trypanosoma in the CSF have been reported from Southern
Sudan and DRC. Additional data are required to docu-
ment the possible interactions between Loa loa and
Trypanosoma, and to evaluate whether the co-infected
patients would have to be treated by ivermectin.
Alcohol consumption
In a number of cases, the relatives of the patients who
developed SAEs reported that the patient had ingested
alcoholic beverages after ivermectin treatment. This is true
for the patient described in [28], who had drunk palm
wine and red wine just after having been treated.
Very few data have been published on the plasma concen-
trations of ivermectin after different doses of ivermectin
[41]. But one may imagine that if alcohol increases the
availability of ivermectin, then the concentration of drug
in the blood would be higher, as would be the effect on
the mf. The first indication that alcohol intake influences
the bioavailability of ivermectin was reported by Edwards
et al., [42] who observed that the systemic availability of a
12-mg dose of ivermectin was approximately doubled
when the dose was in the form of alcoholic solution, as
compared with capsules or tablets. The only study on the
effect of co-ingestion of ivermectin tablets and alcohol
was performed by Shu et al., [43]. These authors com-
pared the plasma ivermectin concentration in two groups
of 10 onchocerciasis patients, one receiving a standard
dose of ivermectin with 750 ml of beer (corresponding to
an average of 400 mg alcohol per kg body weight), and the
other the same dose of ivermectin with 750 ml water. The
dosages of ivermectin were done 1, 3 and 4 hours after
treatment, and showed that the plasma concentrations
were significantly higher in patients who took beer (66.3,
109.0, and 97.2 ng/ml at 1, 3 and 4 h, respectively) than
in those who did not (44.0, 67.5, and 58.7 ng/ml, respec-
tively) (P < 0.01 at each period).
It is clear that the doses of alcohol used by Shu et al., [43]
were fairly low and additional studies should be per-
formed to evaluate the effect of higher quantities of alco-
hol on the bio-availability of ivermectin. In addition,
whether this increased bio-availability is associated with
an increased effect on the Loa microfilaraemia is difficult
to ascertain. Comparisons of the effects of different doses
of ivermectin on Loa have been done by Richard-Lenoble
et al., [44], who compared doses of 5, 10, 30, 50, 100, 150
and 200 µg/kg, Martin-Prével et al., [22], who compared
doses of 300 and 400 µg/kg, and Kamgno et al., [19] with
doses of 50 and 150 µg/kg. Richard-Lenoble et al., [44]
found that the decrease in Loa microfilaraemia at D2 and
D7 were similar after doses of 50, 150 or 200 µg/kg. Mar-
tin-Prével et al., [22] observed that the Loa microfilarial
loads at D2 and D8–10 were lower, although not signifi-
cantly, in those patients who received 400 µg/kg than in
the ones treated at 300 µg/kg. In the last study, where
examinations were done daily from D0 to D7, it was
found that the microfilaraemia never differed significantly
between the two groups of patients, although the counts
in the group treated at the standard dose (150 µg/kg) were
always lower than in the group treated with a low dose of
50 µg/kg [19].
From these results, one may assume that a standard dose
of 150 µg/kg taken with alcohol would have similar
effects that doses above 200 µg/kg, but it is difficult to
assess whether the latter would have more effect on the
Loa mf than the standard dose. However, it is interesting
to keep in mind that the incidence of the "classical" side
effects of ivermectin in onchocerciasis patients does not
seem to be related to the plasma concentration of iver-
mectin [45] and/or the dose received [46,47]. In the two
latter studies, the comparisons were done on doses of 150
and 800 µg/kg. In patients with lymphatic filariasis, the
incidence of reactions is also similar after ivermectinFilaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S4
Page 10 of 13
(page number not for citation purposes)
doses of 50, 100, and 200 µg/kg [48–52], and after doses
of 150 or 400 µg/kg [53].
Lastly, besides the effect of the intake of classical alcoholic
beverages (beer, palm wine, etc.), it would be most useful
to perform studies to evaluate the effect of locally distilled
beverages, which may contain various alcohols, and of
chronic alcoholism, on the bio-availability of ivermectin.
Conclusions
The clinical and biological picture of post-ivermectin SAEs
provides interesting information on the possible physio-
pathogenic processes leading to the condition, and thus to
the best ways to prevent and/or to manage them.
The post-ivermectin Loa-related SAEs are probably not 
due to a direct toxic effect of the drug
As suggested by the title of the notice reporting the first
case [28], one should first consider the possibility of a
direct effect of ivermectin on the CNS. It is known that P-
glycoproteins, which are drug-transporting proteins abun-
dant in the endothelial cells of brain capillaries (part of
the blood-brain barrier, BBB), limit the entry of ivermec-
tin into the brain of normal animals, by transporting the
drug from the inside of the cells to the outside. When
treated with ivermectin, animals presenting a deficiency in
P-glycoproteins develop a toxicosis related to high con-
centrations of the drug in the brain [54,55]. Although the
phenomenon would certainly be rare [56], one may imag-
ine that some individuals present a genetic deficiency in
BBB P-glycoproteins. The spontaneous occurrence of
genetic mutation of BBB P-glycoproteins has been dem-
onstrated in mice [57,58], and is frequent in the collie
dogs [59,60], which are the animals from whom cases of
ivermectin toxicosis are the most frequently reported. In
addition, a polymorphism of MDR1 gene, associated with
a variability of the expression of P-glycoprotein in the
intestine, has been reported in humans [61–64]. How-
ever, there are a number of arguments against the direct
implication of ivermectin in the SAEs reported above.
First, the clinical picture is very different from the one
reported in humans or animals developing an ivermectin
toxicosis. In animals, besides the disorders of conscious-
ness, they show ataxia, mydriasis, vomiting, drooling,
muscle fasciculations, and apparent blindness, whereas in
humans nausea/vomiting, salivation, tachycardia and
hypotension are the most frequent signs of overdose [1].
None of the SAEs reported after a standard dose of iver-
mectin developed such a picture. Second, it would be sur-
prising that a mutation in the MDR1  gene would be
limited to the geographic areas where the cases of SAEs
have been reported.
What are the mechanisms of the post-ivermectin Loa-
related SAEs?
It is clear that the main factor associated with the risk of
post-ivermectin and post-DEC SAEs is the Loa microfilar-
ial load. It is interesting to note that although the out-
comes of these events occurring after ivermectin are
usually less dramatic than those reported after DEC (i.e. in
a simplified manner: 50% death, and 50% recovery with
very serious sequelae), the threshold of microfilaraemia
above which the encephalopathic process may occur is
similar in both cases [30]. The processes which take place
in the two types of SAE might thus well be the same. If this
is the case, and as no pathological information is currently
available for post-ivermectin SAEs, most interesting les-
sons can be drawn from the observations done on autopsy
material of post-DEC fatal encephalopathies [65–68]. It is
considered that these two drugs have different modes of
action, but some similarities also exist between them. The
fact that they provoke the passage of mf into urine and
CSF (and, for O. volvulus mf, into the blood), and that
there is a decrease in the eosinophil counts shortly after
treatment, are such similar features.
Three main mechanisms could be proposed to explain the
post-ivermectin SAEs, and as a matter of fact it is most
likely that all of them occur simultaneously. The first one
would be an obstructive process at the level of the cerebral
microcirculation. The appearance of the retinal lesions
described by Fobi et al., [8], which have also been
described after DEC, would suggest that a similar phe-
nomenon also occurs in the brain. Whether this obstruc-
tion is related to the embolism of great numbers of mf
paralysed by the drug, or to other processes is difficult to
ascertain. The second mechanism would be that the mf,
fleeing from the blood after treatment, go through the
brain capillary endothelium and penetrate into the brain
tissue. Even if the way in which the mf might do so cannot
be explained, it is clear, from pathological observations
done on a patient who died from a post-DEC SAE, that Loa
mf are indeed able to penetrate into the brain tissue [66].
This would explain the diffuse EEG and scan abnormali-
ties which have been observed in those cases which under-
went such examinations. In this respect, one may also
wonder whether the Loa mf do not cross the wall of the
other capillaries to penetrate into all the connective tis-
sues. This would explain the decrease in both the Loa
microfilaraemia, and the eosinophil counts observed after
ivermectin treatment. The third possible mechanism lead-
ing to the post-ivermectin SAEs would be the develop-
ment of inflammatory processes at the cerebral level. It
has been shown that in patients with onchocerciasis or
lymphatic filariasis, the post-filaricide inflammatory reac-
tions may be mediated by the release of products of Wol-
bachia  endosymbionts [69,70]. Indeed, Wolbachia  have
also been found in Loa loa, but in such low quantity thatFilaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S4
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they are unlikely to contribute to the reactions developed
by loiasis patients [71]. The inflammatory processes tak-
ing place in these patients would thus be probably mainly
related to the filariae themselves. The release of Loa anti-
gens, which has been demonstrated after ivermectin treat-
ment [72], may play a role in the process.
How to reduce the pathological processes associated with 
the post-ivermectin Loa-related SAEs?
If the Loa-related post-ivermectin SAEs are partly related to
inflammatory processes similar to the Mazzotti reaction,
one might wonder what treatment would be the best to
limit the phenomenon. The drugs which are the most
often proposed for treatment of post-filaricide reactions
are antihistamines and corticosteroids. Studies performed
in Ghana have shown that antihistamines and indometh-
acin are without effect on the Mazzotti reaction occurring
after DEC treatment of onchocerciasis patients [73,74].
Similarly, diphenhydramine was found to be ineffective
in preventing reactions developing in patients infected
with Wuchereria bancrofti who had been treated with DEC
[75]. However, Carme et al., [76] have observed that when
antihistamines are co-administered with DEC, the severity
(but not the incidence) of reactions is reduced; and Samé-
Ekobo et al., [77] reported that a daily antihistamine treat-
ment by loratidine, during 10 days, brings about a
decrease in the reactions which occurred in onchocerciasis
patients treated with ivermectin.
As opposed to the antihistamines, corticosteroids seem
most useful for dealing with the post-DEC reactions [27].
Anecdotal reports have suggested that these drugs or their
related hormones may have beneficial effects [78]. It has
been shown that starting a course of betamethasone or
prednisone treatment 24–48 hours before the first dose of
DEC in onchocerciasis patients reduces the severity of the
Mazzotti reaction [79]. Awadzi et al., [79,80] have also
demonstrated that treatment with prednisone should be
continued for at least 4 days after the first dose of DEC if
one wants to avoid the rebound in the reaction after stop-
ping the corticosteroids. However, co-administration of
corticosteroids might also delay the destruction of the mf,
and reduce the microfilaricidal activity. This is the reason
why Stingl et al., [74] evaluated whether starting dexame-
thasone treatment after the onset of the Mazzotti reaction
would have an effect on the latter; these authors con-
cluded that this was indeed so, but that the doses of corti-
costeroids had to be tapered rapidly.
If the post-ivermectin Loa-related SAEs are partly related to
inflammatory processes similar to that associated with the
Mazzotti reaction, our results on the changes in the eosi-
nophil counts may suggest that the severity of the reac-
tions could be reduced by administering corticosteroids
within the two days following ivermectin treatment. At
D3, the pathological processes are already in place, and
the use of corticosteroids at that time might be too late to
have any affect on the development of the reaction. Most
of the cases of post-ivermectin SAEs have been managed
using corticosteroids, and it seems that these drugs did not
have any beneficial effect on the course of the condition.
On the contrary, they may lead to the development of
iatrogenic lethal complications. Additional studies should
be performed to provide further information on the
mechanisms of the post-ivermectin Loa-related SAEs. In
this respect, one may consider the possibility of undertak-
ing studies on animal models. The one which would
probably reflect most closely what happens in humans
would be drills (Mandrillus leucophaeus), mandrills (Man-
drillus sphinx) or other monkeys experimentally infected
with human Loa loa, and preferably splenectomised to
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